Document Type: Short Communication

Authors

1 Cancer Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Biostatistics, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Urology Department, Shohada-ye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

Background & Objective: Bladder cancer is the fourth most common cancer in men and the most common cancer in women, comprising 8% of all males and 3% of female tumors. The present study aimed to estimate the five-year survival rates of bladder cancer in Iran.
Methods: Information on3,337 registered cases of bladder cancer was obtained from the Office of National Cancer Registry in the Ministry of Health and Medical Education (MOH & ME). A telephone survey was conducted to gather additional information, such as survival status, demographic, and clinical profile. Kaplan–Meier estimates of five-year survival rates were calculated according to the age of diagnosis, gender, pathological type, and provincial pole.
Results and Conclusion: Overall five-year survival rate was 77%. According to the pathologic type, five-year survival rates were 81%, 66%, 81%, 42%, 77%, and 82% in low-grade urothelial carcinoma, high-grade urothelial carcinoma, adenocarcinoma, undifferentiated carcinomas, Squamous Cell Carcinomas (SCCs), and other tumors, respectively. Additionally, those tumors  were 93%, 88%, 81%, 64%, and 44% among patients whose average ages at diagnosis were < 50, 50–59, 60–59, 70–79, and > 80 years old, respectively. Our study revealed that age and histological type were the major prognostic factors for survival in patients with bladder cancer. Therefore, given the histologic features of the tumor and patients with advanced age, a continuous screening would be highly warranted.  

Keywords

Main Subjects

  1. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, et al. Bladder cancer. The Lancet. 2016;388(10061):2796-810. doi: 10.1016/S0140-6736(16)30512-8. Epub 2016 Jun 23. [DOI:10.1016/S0140-6736(16)30512-8]
  2. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nature reviews Disease primers. 2017;3(1):1-19. [DOI:10.1038/nrdp.2017.22] [PMID]
  3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. [DOI:10.3322/caac.21492] [PMID]
  4. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. European urology. 2017;71(1):96-108. [DOI:10.1016/j.eururo.2016.06.010] [PMID]
  5. Yavari P, Sadrolhefazi B, Mohagheghi MA, al e. A descriptive retrospective study of bladder cancer at a hospital in Iran (1973-2003). Asian Pac J Cancer Prev. 2009;10:681-4.
  6. Grayson M. Bladder cancer. Nature. 2017;551(7679):S33-S. [DOI:10.1038/551S33a] [PMID]
  7. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. The Lancet. 2009;374(9685):239-49. [DOI:10.1016/S0140-6736(09)60491-8]
  8. DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. American family physician. 2017;96(8):507-14.
  9. Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nature reviews Disease primers. 2017;3:17022. [DOI:10.1038/nrdp.2017.22] [PMID]
  10. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN guidelines insights: bladder cancer, version 5.2018. Journal of the National Comprehensive Cancer Network. 2018;16(9):1041-53. [DOI:10.6004/jnccn.2018.0072] [PMID]
  11. Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. The Journal of urology. 2017;198(3):552-9. [DOI:10.1016/j.juro.2017.04.086] [PMID] [PMCID]
  12. Rose TL, Deal AM, Nielsen ME, Smith AB, Milowsky MI. Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. Cancer. 2016;122(13):2012-20. [DOI:10.1002/cncr.30029] [PMID] [PMCID]
  13. Cheng L, Neumann RM, Scherer BG, Weaver AL, Leibovich BC, Nehra A, et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer. 1999;85(12):2638-47. https://doi.org/10.1002/(SICI)1097-0142(19990615)85:123.0.CO;2-V [DOI:10.1002/(SICI)1097-0142(19990615)85:123.0.CO;2-V]
  14. Afshar N, English DR, Thursfield V, Mitchell PL, Te Marvelde L, Farrugia H, et al. Differences in cancer survival by sex: a population-based study using cancer registry data. Cancer Causes & Control. 2018;29(11):1059-69. [DOI:10.1007/s10552-018-1079-z] [PMID]
  15. Cumberbatch MG, Cox A, Teare D, Catto JW. Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015;1(9):1282-90. [DOI:10.1001/jamaoncol.2015.3209] [PMID]
  16. Etemadi A, Sadjadi A, Semnani S, Nouraie SM, Khademi H, Bahadori M. Cancer registry in Iran: a brief overview. Arch Iran Med. 2008;11(5):577-80.
  17. Jafari-Koshki T, Arsang-Jang S, Mahaki B. Bladder cancer in Iran: Geographical distribution and risk factors. Iranian Journal of Cancer Prevention. 2017;10(2). [DOI:10.5812/ijcp.5610]
  18. Mousavi S, Guya M, Ramazani R. Cancer registration report, for year 2006. Cancer Office CoN-cDC, editor Tehran: Ministry of Health and Medical Education. 2007.
  19. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, et al. Bladder cancer. The Lancet. 2016;388(10061):2796-810. [DOI:10.1016/S0140-6736(16)30512-8]
  20. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71(1):96-108. [DOI:10.1016/j.eururo.2016.06.010] [PMID]
  21. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. European urology. 2018;74(6):784-95. [DOI:10.1016/j.eururo.2018.09.001] [PMID]
  22. Wong MC, Fung FD, Leung C, Cheung WW, Goggins WB, Ng C. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Scientific reports. 2018;8(1):1-12. [DOI:10.1038/s41598-018-19199-z] [PMID] [PMCID]
  23. Cumberbatch MG, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Translational andrology and urology. 2019;8(1):5. [DOI:10.21037/tau.2018.09.11] [PMID] [PMCID]
  24. Viegas O, Pinho O, Ferreira IM. Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons and Modulation by Coffee Compounds. Coffee2019. p. 567-78. [DOI:10.1039/9781788015028-00567]
  25. Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354(6312):618-22. [DOI:10.1126/science.aag0299] [PMID] [PMCID]
  26. Allen AM, Oncken C, Hatsukami D. Women and Smoking: The Effect of Gender on the Epidemiology, Health Effects, and Cessation of Smoking. Curr Addict Rep. 2014;1(1):53-60. [DOI:10.1007/s40429-013-0003-6] [PMID] [PMCID]
  27. Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. International Journal of Urology. 2017;24(10):730-4. [DOI:10.1111/iju.13376] [PMID]
  28. Rafiemanesh H, Lotfi Z, Bakhtazad S, Ghoncheh M, Salehiniya H. The epidemiological and histological trend of bladder cancer in Iran. Journal of Cancer Research and Therapeutics. 2018;14(3):532-6. [DOI:10.4103/0973-1482.172134] [PMID]
  29. Andreassen BK, Grimsrud TK, Haug ES. Bladder cancer survival: Women better off in the long run. Eur J Cancer. 2018;95:52-8. [DOI:10.1016/j.ejca.2018.03.001] [PMID]
  30. Tang F, He Z, Lu Z, Wu W, Chen Y, Wei G, et al. Application of nomograms in the prediction of overall survival and cancer‑specific survival in patients with T1 high‑grade bladder cancer. Experimental and therapeutic medicine. 2019;18(5):3405-14. [DOI:10.3892/etm.2019.7979] [PMID] [PMCID]
  31. Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219-27. [DOI:10.1002/cncr.28147] [PMID] [PMCID]
  32. Sabermahani A, Barouni M, Seyedin H, Aryankhesal A. Provincial human development index, a guide for efficiency level analysis: the case of iran. Iran J Public Health. 2013;42(2):149-57.